Tag: cancer

A worrying exception to progress

Cancer survival rates have improved dramatically over the past few decades.
Earlier detection, better treatments, and declining smoking rates have saved millions of lives.

But scientists say one type of cancer is moving in the opposite direction — and it’s affecting younger people.

New research shows that while deaths from most cancers are falling, colon cancer is becoming more deadly for people under the age of 50.
In fact, it is now the leading cause of cancer-related death in this age group.

That shift marks a sharp break from decades of progress in cancer care.

What the data shows

According to a recent report from the American Cancer Society, overall cancer death rates among under-50s dropped by 44 percent between 1990 and 2023.

Four of the five deadliest cancers in younger adults followed that downward trend.
Colorectal cancer did not.

Instead, deaths from colon and rectal cancers have increased by roughly two percent per year, quietly reshaping cancer risk for younger generations.

From fifth place to the deadliest

In 1990, colorectal cancer ranked fifth among cancer deaths in people under 50.
Today, it sits at the top.

It is now the leading cause of cancer death in younger men and the second-leading cause in younger women, behind breast cancer — despite long being considered a disease of older age.

That matters because many younger patients, and even some clinicians, don’t initially suspect cancer.

Why younger patients are at higher risk

One major factor is delayed diagnosis.
Routine screening for colorectal cancer typically begins at age 45, even after guidelines were lowered in response to rising cases.

People under that threshold are less likely to be screened and more likely to dismiss symptoms.

Bloating, blood in stool, abdominal pain, or changes in bowel habits are often attributed to stress, diet, or conditions like IBS, rather than cancer.

What experts are saying

Gastrointestinal cancer specialist Jeff Meyerhardt told Scientific American that colorectal cancer has long been viewed as a cancer of aging.

“That assumption held for decades,” he said, “until more recently.”

The concern now is that tumors in younger patients may go unnoticed for years before diagnosis.

How early does the disease begin?

Researchers are also questioning how colorectal cancer develops so early in life.
For someone diagnosed in their early 20s, scientists estimate precancerous growths may have started in childhood.

Andrea Cercek, co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer, says that possibility is driving urgent research.

“If a 22-year-old has cancer, that process likely began when they were a child,” she explained.

Possible causes under investigation

There is no single confirmed cause for the rise in early-onset colorectal cancer.
Researchers are examining several large-scale changes over the past 30 years.

These include diet, physical inactivity, obesity, antibiotic use, gut microbiome changes, and environmental exposures such as microplastics.

What’s often overlooked is that these factors may interact over time, accelerating disease development in younger bodies.

Why awareness matters now

Survival outcomes for young adults with colorectal cancer can be life-altering, physically and emotionally.
Late diagnosis often means more aggressive treatment and reduced quality of life.

Experts stress that recognizing symptoms early remains the most effective way to reverse the trend.

The earlier colorectal cancer is found, the more treatable it becomes.

What younger people should know

Doctors urge anyone — regardless of age — to seek medical advice for persistent bowel changes, unexplained bleeding, ongoing bloating, or abdominal pain.

These symptoms don’t automatically mean cancer.
But ignoring them has become increasingly risky.

As scientists continue searching for answers, awareness may be the most powerful tool currently available.

Health Disclaimer
This article is for informational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before making any changes to your health, diet, or treatment.

Featured Image Credit: Getty Stock Images

Topics: Cancer, Health, Science, Colon cancer

Pancreatic cancer remains one of the most difficult cancers to treat. Survival rates are low, and treatment options are limited, leaving patients and families with few reasons for optimism.

That is why a new study from Spain is drawing attention across the scientific community. Researchers say they have achieved the complete and lasting disappearance of pancreatic tumors in mice using an experimental treatment approach.

While the findings are early and limited to laboratory models, experts say the results are unlike anything previously reported.

Why pancreatic cancer is so challenging

Pancreatic cancer is often diagnosed late, when the disease has already advanced. According to major cancer research organizations, fewer than one in ten patients survive more than five years after diagnosis.

One of the main reasons is the cancer’s resistance to treatment. Tumors adapt quickly, making many therapies less effective over time.

This resistance has been a major obstacle for decades, particularly in cancers driven by specific genetic mutations.

The new study focuses on the KRAS oncogene, a genetic mutation found in around 90 percent of pancreatic cancer cases.

KRAS plays a key role in driving tumor growth. Scientists have long tried to target it, but success has been limited because tumors often find ways around single-drug treatments.

Previous attempts showed initial promise, only for the cancer to return within months.

Instead of targeting KRAS in one way, the Spanish research team used a combination of three drugs designed to block the gene at multiple points.

The idea was to make it harder for the tumor to adapt. By attacking the cancer from several angles at once, researchers hoped to prevent resistance from developing.

This multi-layered approach is what sets the study apart from earlier efforts.

What the study found

When tested in mice with pancreatic cancer, the treatment led to a complete elimination of tumors. Even more striking, the tumors did not return after treatment ended.

Researchers reported no major side effects in the animals, an important factor when considering future development.

In their published findings, the scientists described the results as a potential pathway toward designing new combination therapies for pancreatic cancer.

Why the findings matter

Permanent tumor disappearance is rarely seen in pancreatic cancer research, even in animal models. That is why the study has generated cautious optimism.

The lead researcher, Dr Mariano Barbacid, is well known for his work in cancer genetics, including the identification of the first human oncogene.

Experts say the team’s reputation and the rigor of the study add weight to the findings, even at this early stage.

Important limitations to note

Despite the excitement, researchers are clear about the study’s limits. The treatment has not been tested in humans, and clinical trials are not yet underway.

Dr Barbacid has emphasized that translating the findings to human patients will not be simple. Human biology is more complex, and treatments that work in mice often fail in clinical settings.

The study is best viewed as a foundation rather than a finished solution.

What happens next

The researchers say their findings could guide the development of future clinical trials. Before that can happen, additional laboratory studies are needed to confirm safety and effectiveness.

Regulatory approval, dosage testing, and long-term monitoring would all be required before human trials could begin.

Still, experts say the approach offers a promising direction for future pancreatic cancer research.

Why cautious optimism matters

Breakthroughs in cancer research often come in small steps rather than sudden cures. While headlines may focus on dramatic results, scientists stress the importance of measured expectations.

This study does not mean pancreatic cancer has been cured. It does suggest, however, that new strategies may be able to overcome obstacles that once seemed insurmountable.

For a disease with so few effective options, that alone represents meaningful progress.

A hopeful signal for the future

Pancreatic cancer has long been associated with grim statistics and limited advances. Studies like this show that innovation is still happening behind the scenes.

Researchers around the world continue to explore new ways to target aggressive cancers at their genetic roots.

While patients will need to wait for further developments, the study offers a rare note of hope in a field where breakthroughs are hard won.

Health Disclaimer
This article is for informational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before making any changes to your health, diet, or treatment.

Featured Image Credit: Getty Stock Images

Topics: Cancer, Health, Science